ASCO

Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study

May 31st 2020

Article

When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Rituximab Biosimilar Demonstrates Similarity in ASCO Study

May 31st 2020

Article

The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

US Needs Drug Negotiating Power, ASCO Study Concludes

May 31st 2020

Article

Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation at the American Society of Clinical Oncology.

Higher Value Oncology Care Is Needed, VA Doctor Says at ASCO

May 30th 2020

Article

Devika Das, MBBS, reviews the evidence presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, and concludes that some deep reforms are needed in oncology care to improve access.

Money and Control Influence Oncologists' Use of Biosimilars

May 30th 2020

Article

Abstracts presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.

Prestige BioPharma's Trastuzumab Demonstrates Equivalence

May 29th 2020

Article

Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab, based on findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds

May 29th 2020

Article

A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.

Amgen's Trastuzumab Biosimilar, Kanjinti, Clinically Similar to Herceptin in Cardiac Safety

June 6th 2019

Article

During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European Union under the name Kanjinti), versus the reference trastuzumab, Herceptin.

Developers Provide Updates on 3 Biosimilar Pegfilgrastim Programs

June 5th 2019

Article

Multiple biosimilars of pegfilgrastim are available in both the United States and Europe, and the field of competitors to Amgen’s brand-name Neulasta continues to expand. During the 2019 American Society of Clinical Oncology Annual Meeting, 3 research teams shared their findings on biosimilar pegfilgrastim development programs from sponsors Sandoz, Fresenius Kabi, and Gema Biotech.

Real-World Data Underscore the Safety and Highlight the Acceptance of Biosimilar Rituximab

June 4th 2019

Article

While no biosimilar rituximab products have yet become available in the United States, biosimilar rituximab products are available in the European Union, and data on their use, published concurrently with the 2019 American Society of Clinical Oncology Annual Meeting, highlight not only their safety but also their growing acceptance among prescribers in Europe.